AstraZeneca aims to expand in Japan

12 February 2001

AstraZeneca is looking to launch more than 15 new treatments in Japanover the next three years and increase its number of sales representatives from 1,000 to 1,500, according to the Nikkei Weekly. AstraZeneca KK currently sells Accolate (zafirlukast), Arimidex (anastrozole) and Losec/Prilosec (omeprazole).

R&D spending at AstraZeneca's Japanese unit is expected to rise 25% to 10 billion yen ($87.2 million), as the company looks to carry out more domestic clinical trials on treatments in the initial phase of development.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight